Bone Regeneration – Discover Pharma

Welcome to Discover Pharma! Today is : October 12, 2026

Bone Regeneration

Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas
Novadip secures €10.4M to advance pivotal Phase 3 trial
Novadip Biosciences has secured €10.4 million in convertible financing to [...]

September 21, 2026
Advanced Therapies,Clinical & Regulatory,Therapeutic Areas
Rare bone disorder: Novadip reports long-term success for pediatric patients treated under compassionate use programme
Novadip Biosciences and Cliniques universitaires Saint-Luc have reported successful long-term [...]

May 5, 2026
Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development
Novadip’s autologous cell therapy NVD003 receives RMAT designation for rare pediatric bone disorder
FDA recognises regenerative approach for congenital pseudarthrosis of the tibia [...]

May 5, 2026
Clinical & Regulatory
Novadip’s ‘off-the-shelf’ spine fusion product shows early efficacy and safety in studies
May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK